Published in Am J Clin Dermatol on June 01, 2013
Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. Clin Exp Med (2015) 0.92
Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells. Melanoma Res (2015) 0.78
Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2. Medicine (Baltimore) (2015) 0.76
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. Oncotarget (2016) 0.75
Comparison of cytotoxicity between extracts of Clinacanthus nutans (Burm. f.) Lindau leaves from different locations and the induction of apoptosis by the crude methanol leaf extract in D24 human melanoma cells. BMC Complement Altern Med (2016) 0.75
Anorectal melanoma metastatic to the breast: a case report and review of the literature. Onco Targets Ther (2016) 0.75
Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer Med (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity (2009) 6.11
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 5.66
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol (2009) 4.19
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 2.05
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (2005) 2.01
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc (2006) 1.99
Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene (2008) 1.94
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun (2002) 1.80
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol (2007) 1.79
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother (2004) 1.77
Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol (2006) 1.70
CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol (2009) 1.70
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol (2007) 1.63
Transient T cell depletion causes regression of melanoma metastases. J Transl Med (2008) 1.61
Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer (2006) 1.60
BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol (2003) 1.59
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A (2010) 1.53
Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52
Treatment of metastatic malignant melanoma. Curr Treat Options Oncol (2005) 1.49
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Long-term survival in stage IV melanoma after repetitive surgical therapy. Onkologie (2008) 1.41
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol (2012) 1.34
A new era: melanoma genetics and therapeutics. J Pathol (2010) 1.32
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol (2006) 3.28
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis (2011) 2.98
OXI1 kinase is necessary for oxidative burst-mediated signalling in Arabidopsis. Nature (2004) 2.45
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 1.64
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Chemokines and cancer. Cancer Invest (2002) 1.40
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol (2008) 1.20
The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol (2005) 1.13
Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther (2004) 1.12
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer (2011) 1.04
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother (2007) 1.04
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine (2006) 1.02
Pox viral vaccine approaches. Semin Oncol (2005) 0.98
Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther (2008) 0.97
Management of metastatic malignant melanoma of the bladder. Urology (2003) 0.95
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Statistical methods on detecting differentially expressed genes for RNA-seq data. BMC Syst Biol (2011) 0.95
Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity. J Immunol (2002) 0.93
Immunotherapy for melanoma. Clin Dermatol (2004) 0.91
CEA-based vaccines. Expert Rev Vaccines (2002) 0.88
The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther (2006) 0.87
Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine (2007) 0.86
Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol (2008) 0.86
Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther (2010) 0.86
Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines (2006) 0.86
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol (2006) 0.86
Poxviruses as vectors for cancer immunotherapy. Curr Opin Drug Discov Devel (2003) 0.86
Gene therapy with poxvirus vectors. Curr Opin Mol Ther (2005) 0.86
TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccin (2010) 0.86
Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol (2002) 0.86
Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother (2009) 0.85
The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2015) 0.84
Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol (2015) 0.84
Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. BMC Med Genomics (2013) 0.84
Surgical treatment of stage IV melanoma. Clin Dermatol (2004) 0.83
Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles. Cancer Gene Ther (2004) 0.83
Imaging the immune response to monitor tumor immunotherapy. Expert Rev Vaccines (2009) 0.82
A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther (2009) 0.82
Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther (2004) 0.81
Current approaches to novel therapeutics in pancreatic cancer. Invest New Drugs (2003) 0.81
Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res (2009) 0.81
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother (2011) 0.81
Cytokine therapy for cancer. Surg Oncol Clin N Am (2007) 0.80
Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol (2007) 0.80
Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology (2012) 0.79
Evaluating medical, percutaneous coronary intervention, and coronary artery bypass surgery options for chronic angina: an update of the revised guidelines. Rev Cardiovasc Med (2009) 0.79
Vaccines for colorectal cancer and renal cell carcinoma. Cancer J (2011) 0.79
Gene therapy for antitumor vaccination. Methods Mol Biol (2009) 0.79
An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther (2011) 0.78
TroVax(®) vaccine therapy for renal cell carcinoma. Immunotherapy (2012) 0.78
Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine (2004) 0.78
Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. J Transl Med (2014) 0.78
Local delivery of poxvirus vaccines for melanoma. Semin Cancer Biol (2003) 0.78
High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. J Interferon Cytokine Res (2014) 0.77
Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection. Breast J (2005) 0.77
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest (2016) 0.77
Viral vaccines for cancer immunotherapy. Hematol Oncol Clin North Am (2006) 0.77
Intratumoral Approaches for the Treatment of Melanoma. Cancer J (2017) 0.76
Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther (2002) 0.76
TG-4010 Transgene. Curr Opin Investig Drugs (2004) 0.76
HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice. AIDS Res Hum Retroviruses (2014) 0.76
Integrating bench with bedside: the role of vaccine therapy in the treatment of solid tumors. J Clin Oncol (2004) 0.76
Chemokines in tumor immunotherapy. Front Biosci (2006) 0.76
The contralateral sentinel node. Can J Surg (2005) 0.75
Administration of vaccinia virus to mice may cause contact or bedding sentinel mice to test positive for orthopoxvirus antibodies: case report and follow-up investigation. Comp Med (2003) 0.75
Recurrent Cervical Cancer Presenting as Inflammatory Breast Cancer. Am Surg (2016) 0.75
Gastric Adenocarcinoma Presenting after Revisional Roux-en-Y Gastric Bypass. Am Surg (2016) 0.75
Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control (2013) 0.75
Single-incision laparoscopic surgery for intra-abdominal metastatic melanoma. Am Surg (2011) 0.75